• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脓毒症中的免疫血栓形成:细胞间相互作用、分子触发因素及治疗机会——综述

Immunothrombosis in Sepsis: Cellular Crosstalk, Molecular Triggers, and Therapeutic Opportunities-A Review.

作者信息

Aklilu Addis, Lai Michael Siu-Lun, Jiang Zhiwei, Yip Shea Ping, Huang Chien-Ling

机构信息

Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China.

出版信息

Int J Mol Sci. 2025 Jun 25;26(13):6114. doi: 10.3390/ijms26136114.

DOI:10.3390/ijms26136114
PMID:40649892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12249991/
Abstract

Sepsis remains a critical global health challenge characterized by life-threatening organ dysfunction arising from a dysregulated host response to infection. Immunothrombosis refers to the intersection of immune activation and coagulation pathways, particularly relevant in the context of sepsis. A growing body of evidence identifies immunothrombosis, a tightly interwoven process between innate immunity and coagulation. While immunothrombosis serves as a host defense mechanism under physiological conditions, its aberrant activation in sepsis precipitates microvascular thrombosis, organ ischemia, and progression toward disseminated intravascular coagulation (DIC). This review provides a comprehensive overview of the cellular contributors to immunothrombosis, including neutrophils, monocytes, platelets, and endothelial cells, and elucidates the signaling cascades, such as nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), and inflammasome activation, that govern their interplay. We further highlight emerging molecular mediators, including extracellular traps, tissue factor expression, and cytokine amplification loops, that collectively promote pathological thromboinflammation. A deeper understanding of these interconnected pathways offers critical insights into the pathogenesis of sepsis and unveils potential targets for timely intervention. Ultimately, this review aims to bridge immunological and hematological perspectives to inform the development of novel therapeutic strategies against sepsis-induced coagulopathy.

摘要

脓毒症仍然是一项严峻的全球健康挑战,其特征是宿主对感染的反应失调引发危及生命的器官功能障碍。免疫血栓形成是指免疫激活和凝血途径的交叉,在脓毒症背景下尤为相关。越来越多的证据表明免疫血栓形成是先天免疫和凝血之间紧密交织的过程。虽然免疫血栓形成在生理条件下起宿主防御机制的作用,但其在脓毒症中的异常激活会引发微血管血栓形成、器官缺血以及向弥散性血管内凝血(DIC)的进展。本综述全面概述了免疫血栓形成的细胞贡献者,包括中性粒细胞、单核细胞、血小板和内皮细胞,并阐明了控制它们相互作用的信号级联反应,如核因子κB(NF-κB)、丝裂原活化蛋白激酶(MAPK)和炎性小体激活。我们还强调了新兴的分子介质,包括细胞外陷阱、组织因子表达和细胞因子放大环,它们共同促进病理性血栓炎症。对这些相互关联途径的更深入理解为脓毒症的发病机制提供了关键见解,并揭示了及时干预的潜在靶点。最终,本综述旨在弥合免疫学和血液学观点,为开发针对脓毒症诱导的凝血病的新型治疗策略提供依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/f8fd3f424909/ijms-26-06114-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/b0f570fe5bf1/ijms-26-06114-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/ae9961a548fe/ijms-26-06114-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/f98999de52f1/ijms-26-06114-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/f8fd3f424909/ijms-26-06114-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/b0f570fe5bf1/ijms-26-06114-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/ae9961a548fe/ijms-26-06114-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/f98999de52f1/ijms-26-06114-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e9c/12249991/f8fd3f424909/ijms-26-06114-g004.jpg

相似文献

1
Immunothrombosis in Sepsis: Cellular Crosstalk, Molecular Triggers, and Therapeutic Opportunities-A Review.脓毒症中的免疫血栓形成:细胞间相互作用、分子触发因素及治疗机会——综述
Int J Mol Sci. 2025 Jun 25;26(13):6114. doi: 10.3390/ijms26136114.
2
Thromboinflammation vs. immunothrombosis: strategies for overcoming anticoagulant resistance in COVID-19 and other hyperinflammatory diseases. Is ROTEM helpful or not?血栓炎症与免疫血栓形成:克服COVID-19和其他高炎症性疾病中抗凝抵抗的策略。旋转血栓弹力图(ROTEM)是否有用?
Front Immunol. 2025 Jun 19;16:1599639. doi: 10.3389/fimmu.2025.1599639. eCollection 2025.
3
Systemic Inflammatory Response Syndrome全身炎症反应综合征
4
Prognostic gene landscapes and therapeutic insights in sepsis-induced coagulopathy.脓毒症诱导性凝血功能障碍的预后基因图谱和治疗新视角。
Thromb Res. 2024 May;237:1-13. doi: 10.1016/j.thromres.2024.03.011. Epub 2024 Mar 12.
5
Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.2025年弥散性血管内凝血的更新定义与评分:国际血栓与止血学会弥散性血管内凝血分会科学标准化委员会的交流意见
J Thromb Haemost. 2025 Apr 9. doi: 10.1016/j.jtha.2025.03.038.
6
Immunological role of Gas6/TAM signaling in hemostasis and thrombosis.Gas6/TAM 信号在止血和血栓形成中的免疫作用。
Thromb Res. 2024 Jun;238:161-171. doi: 10.1016/j.thromres.2024.05.002. Epub 2024 May 3.
7
cGAS-STING targeting offers novel therapeutic regimen in sepsis-associated organ dysfunction.靶向cGAS-STING为脓毒症相关器官功能障碍提供了新的治疗方案。
Cell Biol Toxicol. 2025 Jul 3;41(1):113. doi: 10.1007/s10565-025-10051-5.
8
The Role of Protein Ubiquitination in the Onset and Progression of Sepsis.蛋白质泛素化在脓毒症发生发展中的作用
Cells. 2025 Jul 2;14(13):1012. doi: 10.3390/cells14131012.
9
Hail Lifestyle Medicine consensus position statement as a medical specialty: Middle Eastern perspective.欢呼将生活方式医学作为一门医学专业的共识立场声明:中东视角。
Front Public Health. 2025 Jun 20;13:1455871. doi: 10.3389/fpubh.2025.1455871. eCollection 2025.
10
Clot-Targeted Nanogels for Dual-Delivery of AntithrombinIII and Tissue Plasminogen Activator to Mitigate Disseminated Intravascular Coagulation Complications.用于双重递送抗凝血酶 III 和组织型纤溶酶原激活剂的靶向血栓的纳米凝胶,以减轻弥漫性血管内凝血并发症。
ACS Nano. 2024 Jun 18;18(24):15517-15528. doi: 10.1021/acsnano.4c00162. Epub 2024 Jun 5.

本文引用的文献

1
Development of indole derivatives as inhibitors targeting STING-dependent inflammation.作为靶向STING依赖性炎症抑制剂的吲哚衍生物的开发。
Bioorg Med Chem. 2025 Aug 15;126:118216. doi: 10.1016/j.bmc.2025.118216. Epub 2025 Apr 27.
2
Immunothrombolytic monocyte-neutrophil axes dominate the single-cell landscape of human thrombosis and correlate with thrombus resolution.免疫溶栓单核细胞-中性粒细胞轴主导人类血栓形成的单细胞格局,并与血栓溶解相关。
Immunity. 2025 May 13;58(5):1343-1358.e13. doi: 10.1016/j.immuni.2025.03.020. Epub 2025 Apr 24.
3
Exosomes and MicroRNAs: key modulators of macrophage polarization in sepsis pathophysiology.
外泌体与微小RNA:脓毒症病理生理学中巨噬细胞极化的关键调节因子
Eur J Med Res. 2025 Apr 17;30(1):298. doi: 10.1186/s40001-025-02561-z.
4
Systemic Inflammatory Response Syndrome, Thromboinflammation, and Septic Shock in Fetuses and Neonates.胎儿和新生儿的全身炎症反应综合征、血栓炎症和感染性休克
Int J Mol Sci. 2025 Apr 1;26(7):3259. doi: 10.3390/ijms26073259.
5
Clinical characteristics, and outcomes of severe neonatal thrombocytopenia: a retrospective cohort study in China.重症新生儿血小板减少症的临床特征及结局:一项中国的回顾性队列研究
BMC Pediatr. 2025 Apr 4;25(1):275. doi: 10.1186/s12887-025-05640-6.
6
Promote Sepsis Recovery through the Inhibition of Immunothrombosis via a Combination of Probenecid Nanocrystals and Cefotaxime Sodium.通过丙磺舒纳米晶体与头孢噻肟钠联合抑制免疫血栓形成促进脓毒症恢复。
ACS Appl Mater Interfaces. 2025 Apr 9;17(14):21013-21032. doi: 10.1021/acsami.5c05609. Epub 2025 Mar 28.
7
[Unveiling the molecular features and diagnosis and treatment prospects of immunothrombosis via integrated bioinformatics analysis].[通过综合生物信息学分析揭示免疫性血栓形成的分子特征及诊断与治疗前景]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2025 Mar;41(3):228-235.
8
Enhanced prediction of thrombotic events in hospitalized COVID-19 patients with soluble thrombomodulin.可溶性血栓调节蛋白增强对住院COVID-19患者血栓形成事件的预测
PLoS One. 2025 Mar 19;20(3):e0319666. doi: 10.1371/journal.pone.0319666. eCollection 2025.
9
Neutrophils: Linking Inflammation to Thrombosis and Unlocking New Treatment Horizons.中性粒细胞:连接炎症与血栓形成并开拓新的治疗前景
Int J Mol Sci. 2025 Feb 25;26(5):1965. doi: 10.3390/ijms26051965.
10
Role of peak D-dimer in predicting mortality and venous thromboembolism in COVID-19 patients.D-二聚体峰值在预测COVID-19患者死亡率和静脉血栓栓塞中的作用。
Sci Prog. 2025 Jan-Mar;108(1):368504241247982. doi: 10.1177/00368504241247982.